Accro Bioscience

aid: accrobioscience
name: Accro Bioscience
description: 'Accro Bioscience (Suzhou) Limited, trading as Accropeutics, is a clinical-stage biopharmaceutical company founded
  in 2017 with operations in Suzhou, China and New York. It develops small-molecule therapeutics against regulated cell death
  — necroptosis, pyroptosis and ferroptosis — targeting the cell-death-to-inflammation loop behind inflammatory, fibrotic,
  autoimmune and oncology disease. Its pipeline is led by AC-101, an oral selective RIPK2 inhibitor in Phase Ib for ulcerative
  colitis with FDA clearance for a Phase II multi-regional IBD study; AC-201, a TYK2/JAK1 pseudokinase inhibitor licensed
  to Fosun Pharma for Greater China as FXS5626; and AC-003, a RIPK1 inhibitor in Phase Ib for acute graft-versus-host disease
  with FDA Orphan Drug Designation. It closed a $50M Series C led by OrbiMed in May 2026. Accro Bioscience sells drug candidates,
  not software: it runs no developer program and publishes no API, SDK or machine-readable API contract.'
url: https://raw.githubusercontent.com/api-evangelist/accrobioscience/refs/heads/main/apis.yml
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  probe_state: none
  source:
  - security
  generated: '2026-11-06'
  method: derived
image: https://www.accropeutics.com/upload/2024-05/171677317462138100.svg
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-09-06'
modified: '2026-09-06'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Drug Discovery
- Clinical Trials
- Life Sciences
- Immunology
- inflammation
- Small Molecule
- Regulated Cell Death
tags_raw:
- Company
- Biotechnology
- Pharmaceuticals
- Drug Discovery
- Clinical Trials
- Life Sciences
- Immunology
- Inflammation
- Small Molecule
- Regulated Cell Death
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/accrobioscience-domain-security.yml
- type: Website
  url: https://www.accropeutics.com/
- type: About
  url: https://www.accropeutics.com/about
- type: Newsroom
  url: https://www.accropeutics.com/news
- type: Contact
  url: https://www.accropeutics.com/contact
- type: Partners
  url: https://www.accropeutics.com/partnerships
- type: Careers
  url: https://www.accropeutics.com/join
- type: LinkedIn
  url: https://www.linkedin.com/company/95295041/
- type: SecondaryMarket
  url: https://equityzen.com/company/accrobioscience
x-enrichment:
  date: '2026-09-06'
  status: minimal
  artifacts_added: 2
  pass: local-v3
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Accro Bioscience (Suzhou) Limited is a clinical-stage biopharmaceutical company whose product is a small-molecule
    drug pipeline (AC-101, AC-201, AC-003), not software; its entire public surface is the accropeutics.com corporate site
    — about, focus areas, pipeline, partnerships, news, join us, contact — with no developer, docs, portal or integration
    link anywhere in the nav or footer, and the site does not even serve a /robots.txt or /sitemap.xml. Every REST/GraphQL/agent-card,
    /llms.txt and /.well-known/ path probed on both www.accropeutics.com and accropeutics.com returns an identical 548-byte
    hard 404, verified against a random control path returning the same body and byte count; api., dev., docs., developer.,
    portal., data. and mcp..accropeutics.com do not resolve in DNS, and there is no GitHub organization and no npm or PyPI
    package under either the Accro Bioscience or Accropeutics name.
  evidence:
  - url: https://www.accropeutics.com/
    status: 200
  - url: https://www.accropeutics.com/openapi.json
    status: 404
  - url: https://www.accropeutics.com/swagger.json
    status: 404
  - url: https://www.accropeutics.com/api-docs
    status: 404
  - url: https://www.accropeutics.com/graphql
    status: 404
  - url: https://www.accropeutics.com/developers
    status: 404
  - url: https://www.accropeutics.com/llms.txt
    status: 404
  - url: https://www.accropeutics.com/robots.txt
    status: 404
  - url: https://www.accropeutics.com/.well-known/agent-card.json
    status: 404
  - url: https://www.accropeutics.com/.well-known/agent.json
    status: 404
  - url: https://www.accropeutics.com/.well-known/api-catalog
    status: 404
  - url: https://accropeutics.com/.well-known/security.txt
    status: 404
  - url: https://www.accropeutics.com/zz-api-evangelist-control-7c1e
    status: 404
  - url: https://api.github.com/search/users?q=accro+bioscience
    status: 200
  checked: '2026-09-06'